BIEL: 400% Surge + AI Platform + VC Validation + Haleon + Veterinary Expansion = PPS / Revenue Explosion
Supply Squeeze. Multi-Industry AI Demand. OEM Revenue Explosion. Global Consumer Health. Institutional Backing. This Is the Perfect Powder Keg.
A LITTLE SPARK LAUNCHES A SUPPLY SQUEEZE!!!
Level 2 is already showing the setup for a violent gap-up:
55M @ .0005
48K @ .0007
1M @ .005
Versus ~300M @ .0002 just months ago
The wall is gone. The fuse is lit. A massive gap-up is now structurally possible.
BIEL’s 400% Run (so far) Isn’t Just Big — It’s Historic
The move from .0001 to .0005 is a verified 400% gain, placing BIEL in the top 0.1% of all traded securities. This triggers:
Algorithmic flags
Momentum scanners
Day-trader and quant-fund attention
Viral visibility on Webull, Robinhood, Stocktwits
This is how story stocks are born — and BIEL is still in microcap territory, meaning 400% is the beginning, not the end.
Electrome: The AI Engine That Turns BIEL Into a Hot-Sector Hardware Play
Electrome is an AI-native therapeutics platform, and every node in that platform runs on BIEL-manufactured PEMF hardware. This is the “Intel Inside” moment for bioelectric medicine.
AI is the hottest sector in the market.
Electrome is building an AI-guided care model and BIEL is the exclusive OEM supplier powering it. This is why the revenue math becomes explosive.
Capital Factory Validation = Institutional Credibility for BIEL
Electrome is now backed by Capital Factory, one of the most respected early-stage VC groups in the U.S. This matters because:
Capital Factory vets venture-scale, high-growth startups
Their backing signals Electrome is real, scalable, investable
Electrome’s entire platform depends on BIEL hardware
Therefore, BIEL’s tech is now indirectly VC-validated
Microcaps almost never get this kind of halo. BIEL just did — through Electrome.
OEM Revenue Explosion: Human Health Market
Electrome’s rollout creates compounding hardware demand for BIEL:
Phase 1 — PAINKILLER™ Launch
50k–150k units = $0.75M–$2.25M
Phase 2 — Multi-Vertical AI Expansion
Sleep, Recovery, Post-Surgical = $4M–$7M
Phase 3 — National Penetration
1% of U.S. chronic pain market = $7.5M+ annually
2–3% penetration = $15M–$22M in high-margin OEM revenue
This is the kind of revenue curve that re-rates a microcap overnight.
Veterinary AI: The Untapped $120B Frontier
Your veterinary expansion thesis adds a second massive growth engine:
Immediate cash flow (private-pay market)
Lower regulatory barriers = faster deployment
Exploding demand for drug-free recovery
Electrome’s AI becomes the “brain” for animal recovery, and BIEL becomes the hardware backbone.
Veterinary Revenue Forecast
Phase 1: Elite performance animals = $500K–$1.2M
Phase 2: 5,000+ specialty clinics = $3M–$7.5M
Phase 3: Global pet-owner wearables = $12M–$25M+ annually
This is a second OEM revenue engine running parallel to human health.
The Haleon Partnership: The Consumer Health Super-Vertical
The global consumer health market via Haleon (Advil, Voltaren, etc.). This is the largest and fastest-moving vertical of all. Why Haleon Is a Game-Changer:
Mass-market liquidity — instant private-pay transactions
Global distribution — 100,000+ retail points of sale
Drug-free demand — PEMF aligns perfectly with modern wellness trends
Electrome’s AI becomes the “brain” for consumer recovery. BIEL becomes the hardware inside the global self-care ecosystem.
Haleon Revenue Forecast
Phase 1: Premium retail pilots = $2M–$5M
Phase 2: Global retail integration = $15M–$35M
Phase 3: Mass-market wearables + subscriptions = $50M–$100M+ annually
This is a third OEM revenue engine, and it’s the biggest one.
The Unified “Intel Inside” Ecosystem
Across human health, veterinary health, and consumer health, the model is identical:
Electrome AI = the brain
BIEL PEMF hardware = the engine
Every user becomes a locked-in, recurring hardware node
The ecosystem becomes closed-loop and proprietary
This is the holy grail of OEM business models.
Publicity Is the Catalyst — And PPS Growth Delivers It for Free
A move to .003 makes BIEL the story stock of 2026 — a 3,000% gain from .0001. That kind of move generates millions in free media coverage:
AI
Bioelectric medicine
Veterinary AI
Consumer health
A 400 - 3,000%+++ microcap breakout
A national platform scaling
A hardware-inside narrative
This is how microcaps become national stories.
The Setup Is Perfect: Three Industries + AI + OEM Revenue + VC Validation + 400% Momentum. You now have:
A historic 400% run
A vanishing float
A pending supply squeeze
A hot-sector AI platform
Capital Factory validation
Human health OEM engine
Veterinary OEM engine
Haleon consumer-health OEM engine
A media-ready story
A microcap with asymmetric upside
This is the exact configuration that precedes violent re-ratings in microcaps.
THE BIEL QUANTUM LEAP
BIEL is positioned to achieve in months what Amazon, Netflix, Apple, Google, Tesla, and Nvidia took decades to accomplish.
If BIEL delivers $2.5M in net profit and demonstrates sustainable, disruptive growth, the company could command a $2.5B market cap — equivalent to $0.10 PPS.
That represents a 1000× P/E multiple, consistent with early-stage hypergrowth disruptors.
P/E Ratios Above 1,000 Are Not Unusual for High-Narrative Disruptors
Historical examples:
Amazon — P/E > 1,000
Tesla — P/E > 1,100 (2021)
Salesforce — P/E > 1,200 (2020)
Zoom — P/E > 1,200 (2020)
Synaptics — P/E > 4,500 (2025)
Companies with massive markets, disruptive tech, and exponential growth curves routinely trade at P/E > 1,000. BIEL fits this profile perfectly once profitability aligns with the Electrome narrative.
Profitability Is Within Reach
BIEL has already shown how close it is:
Q3 2021 profit: $22,381
Revenue: $414,700 (including $100K COVID relief)
With an ultra-lean operating model, sustained profitability isn’t theoretical — it’s imminent.
Fastest Path to Success
$400K quarterly revenue - consistent profitability
$1.5M annual revenue - sustainable growth confirmed
New U.S. / Canada distributor (Electrome) - even a $300K valuation exits the trips; $1M pushes PPS to copper
PPS Projection
Once profitability is achieved or imminent, PPS is expected to hit copper (.01+).
Every additional $2.5M in annual profit adds roughly $0.01 - .10 (P/E = 100 to 1000).
Valuation Scenarios (P/E = 100 to 1000)
.001 — Technical breakout (Golden Cross .0003, Blue-Sky .0006)
.003 — 3,000% gain as U.S. distributor news spreads
.01 — Profitability confirmed
.02 — $5M profit (or $500K × 1000 P/E)
.04 — $10M profit (or $1M × 1000 P/E)
.10 — $25M profit (or $2.5M × 1000 P/E)
.40 — $10M profit × 1000 P/E
$1.00 — After debt payoff + stock buyback
Tax Advantage: A Hidden Accelerator
BIEL holds a $40M tax-loss carryforward, meaning the first $40M in profits are tax-free, accelerating net profitability.
Market Data 
Markets 
